Clinical trials: Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
The purpose of this study is to understand how a drug called Linaclotide improves bowel function and abdominal pain in patients with Irritable Bowel Syndrome with Constipation (IBS-C) as well as to examine whether Linaclotide…
- Trial name
- NCT02078323
- Testing
- Linaclotide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Augusta University
Irritable Bowel Syndrome With Constipation
Effect of Tai Chi as Treatment for IBS-C
The purpose of the study is to evaluate the efficacy of Tai Chi practice in reducing symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).
- Trial name
- NCT04132804
- Testing
- Tai Chi
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Irritable Bowel Syndrome With Constipation (IBS-C)
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily…
- Trial name
- NCT05643534
- Testing
- Tenapanor 50 MG, Tenapanor 25 mg bid
- Where
- 39 sites in United States
- Volunteers
- 180 people
- Sponsor
- Ardelyx
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
- Trial name
- NCT00171431
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Bowel Syndrome With Constipation (IBS-C)
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
- Trial name
- NCT06553547
- Testing
- Tenapanor
- Where
- 20 sites in United States
- Volunteers
- 72 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).
- Trial name
- NCT00938717
- Where
- 107 sites in United States
- Volunteers
- 805 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Constipation-predominant Irritable Bowel Syndrome (IBS-C)
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
This study is to investigate the efficacy, safety, and plasma concentration change of ASP0456 in patients with constipation-predominant irritable bowel syndrome.
- Trial name
- NCT01714843
- Testing
- linaclotide
- Where
- 4 sites in Japan
- Volunteers
- 559 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome (IBS-C)
Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C
This study evaluates the efficacy and safety of transcutaneous auricular vagus nerve stimulation (ta-VNS) in adults with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT07662083
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- West Virginia University
Functional Constipation, Irritable Bowel Syndrome With Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria…
- Trial name
- NCT04026113
- Testing
- Linaclotide
- Where
- 115 sites in United States, Belgium and 12 more
- Volunteers
- 438 people
- Sponsor
- AbbVie
Constipation-Predominant Irritable Bowel Syndrome
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT00607971
- Testing
- Renzapride
- Where
- 126 sites in United States
- Volunteers
- 939 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS.
- Trial name
- NCT00258193
- Testing
- MD-1100 Acetate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie